1. Home
  2. RFL vs EDAP Comparison

RFL vs EDAP Comparison

Compare RFL & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFL
  • EDAP
  • Stock Information
  • Founded
  • RFL 2017
  • EDAP 1979
  • Country
  • RFL United States
  • EDAP France
  • Employees
  • RFL N/A
  • EDAP N/A
  • Industry
  • RFL Real Estate
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • RFL Finance
  • EDAP Health Care
  • Exchange
  • RFL Nasdaq
  • EDAP Nasdaq
  • Market Cap
  • RFL 54.4M
  • EDAP 46.7M
  • IPO Year
  • RFL N/A
  • EDAP 1997
  • Fundamental
  • Price
  • RFL $1.34
  • EDAP $1.81
  • Analyst Decision
  • RFL
  • EDAP Buy
  • Analyst Count
  • RFL 0
  • EDAP 3
  • Target Price
  • RFL N/A
  • EDAP $8.50
  • AVG Volume (30 Days)
  • RFL 77.7K
  • EDAP 67.2K
  • Earning Date
  • RFL 12-10-2025
  • EDAP 11-06-2025
  • Dividend Yield
  • RFL N/A
  • EDAP N/A
  • EPS Growth
  • RFL N/A
  • EDAP N/A
  • EPS
  • RFL N/A
  • EDAP N/A
  • Revenue
  • RFL $732,000.00
  • EDAP $74,008,221.00
  • Revenue This Year
  • RFL N/A
  • EDAP N/A
  • Revenue Next Year
  • RFL N/A
  • EDAP N/A
  • P/E Ratio
  • RFL N/A
  • EDAP N/A
  • Revenue Growth
  • RFL 35.56
  • EDAP 1.56
  • 52 Week Low
  • RFL $1.28
  • EDAP $1.21
  • 52 Week High
  • RFL $3.19
  • EDAP $3.08
  • Technical
  • Relative Strength Index (RSI)
  • RFL 45.24
  • EDAP 34.71
  • Support Level
  • RFL $1.32
  • EDAP $2.23
  • Resistance Level
  • RFL $1.44
  • EDAP $2.44
  • Average True Range (ATR)
  • RFL 0.07
  • EDAP 0.24
  • MACD
  • RFL 0.01
  • EDAP -0.04
  • Stochastic Oscillator
  • RFL 28.57
  • EDAP 5.77

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: